A61K 31/4465
Only substituted in position 4
Official title: only substituted in position 4
A61K31/4465 (Only substituted in position 4) appears on 136 US grants and 218 published applications in this corpus.
Search patents in A61K- Granted patents
- 136
- Published applications
- 218
- Assignees
- 119
- Inventors
- 526
- Latest grant
- 23 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 4 |
| 2003 | 3 | 4 |
| 2004 | 2 | 5 |
| 2005 | 2 | 3 |
| 2006 | 4 | 5 |
| 2007 | 4 | 1 |
| 2008 | 1 | 5 |
| 2009 | 1 | 2 |
| 2010 | 0 | 15 |
| 2011 | 1 | 8 |
| 2012 | 4 | 7 |
| 2013 | 7 | 10 |
| 2014 | 5 | 19 |
| 2015 | 13 | 12 |
| 2016 | 6 | 19 |
| 2017 | 14 | 14 |
| 2018 | 7 | 15 |
| 2019 | 14 | 15 |
| 2020 | 7 | 11 |
| 2021 | 7 | 9 |
| 2022 | 3 | 8 |
| 2023 | 8 | 9 |
| 2024 | 2 | 7 |
| 2025 | 6 | 5 |
| 2026 | 0 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Thrombosomes as an antiplatelet agent reversal agent23 Sep 2025US 12,419,914 B2Cellphire, Inc.
- Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs18 Mar 2025US 12,252,459 B2Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd.
- Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound4 Mar 2025US 12,239,638 B2Theravance Biopharma R&D IP, LLC
- Adamantane derivatives for the treatment of filovirus infection4 Mar 2025US 12,240,857 B2Arisan Therapeutics Inc.
- Methods of treating bleeding in a subject treated with an antiplatelet agent28 Jan 2025US 12,208,122 B2Cellphire, Inc.
- Aromatic compounds for use as protein phosphatase 2a (pp2a) modulators10 Sep 2026US 2026/0265190 A1Rappta Therapeutics Oy
- Cancer stratification and treatment20 Aug 2026US 2026/0240831 A1Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia20 Aug 2026US 2026/0242335 A1Atrogi AB
- Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications2 Jul 2026US 2026/0184663 A1NucMito Pharmaceuticals Co. Ltd.
- Dihydroindene derivatives as malt1 inhibitors2 Jul 2026US 2026/0184687 A1C4X Discovery Limited
Most cited
By later US patents
- Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases45US 6,071,970 ANPS Pharmaceuticals, Inc. · 2000
- N-acyl anthranilic acid derivative or salt thereof32US 8,492,582 B2Toyama Chemical Co., Ltd. · 2013
- 3,3-disubstituted piperidines as modulators of chemokine receptor activity31US 6,124,319 AMerck & Co., Inc. · 2000
- Cyclopropylamines as LSD1 inhibitors27US 9,493,442 B2Incyte Corporation · 2016
- Neuropharmacological treatments of sleep-related breathing disorders18US 6,555,564 B1The Board of Trustees of the University of Illinois · 2003